As of 2024-10-12, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -157.59. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 155.85 mil USD. VNDA's TTM EBITDA according to its financial statements is -0.99 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 10.4x - 16.7x | 13.9x |
| Forward P/E multiples | 18.2x - 20.1x | 18.4x |
| Fair Price | 1.59 - 4.70 | 2.99 |
| Upside | -64.2% - 5.8% | -32.7% |
| Date | EV/EBITDA |
| 2024-10-11 | -157.59 |
| 2024-10-10 | -155.82 |
| 2024-10-09 | -159.36 |
| 2024-10-08 | -160.53 |
| 2024-10-07 | -161.12 |
| 2024-10-04 | -168.79 |
| 2024-10-03 | -161.12 |
| 2024-10-02 | -166.43 |
| 2024-10-01 | -163.48 |
| 2024-09-30 | -172.32 |
| 2024-09-27 | -171.14 |
| 2024-09-26 | -175.27 |
| 2024-09-25 | -181.75 |
| 2024-09-24 | -188.24 |
| 2024-09-23 | -175.86 |
| 2024-09-20 | -167.61 |
| 2024-09-19 | -169.97 |
| 2024-09-18 | -187.65 |
| 2024-09-17 | -187.06 |
| 2024-09-16 | -195.31 |
| 2024-09-13 | -196.49 |
| 2024-09-12 | -190.00 |
| 2024-09-11 | -185.88 |
| 2024-09-10 | -189.41 |
| 2024-09-09 | -191.77 |
| 2024-09-06 | -191.77 |
| 2024-09-05 | -195.31 |
| 2024-09-04 | -195.31 |
| 2024-09-03 | -195.31 |
| 2024-08-30 | -207.69 |
| 2024-08-29 | -203.56 |
| 2024-08-28 | -206.51 |
| 2024-08-27 | -211.22 |
| 2024-08-26 | -219.47 |
| 2024-08-23 | -217.71 |
| 2024-08-22 | -208.28 |
| 2024-08-21 | -214.17 |
| 2024-08-20 | -207.10 |
| 2024-08-19 | -211.22 |
| 2024-08-16 | -202.38 |
| 2024-08-15 | -200.61 |
| 2024-08-14 | -197.67 |
| 2024-08-13 | -197.08 |
| 2024-08-12 | -198.26 |
| 2024-08-09 | -201.79 |
| 2024-08-08 | -208.86 |
| 2024-08-07 | -202.38 |
| 2024-08-06 | -208.86 |
| 2024-08-05 | -208.86 |
| 2024-08-02 | -214.17 |